SCHEMBL23540405

SCHEMBL23540405

CC(C)(C)OC(=O)[C@@H](COCc1ccccc1)OS(=O)(=O)C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.46
NPSR1 Q6W5P4 1/20 0.44
CTSS P25774 1/20 0.44
PPARG P37231 1/20 0.42
KLK7 P49862 1/20 0.40
KLK5 Q9Y337 1/20 0.40
SYK P43405 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CA1 P00915 3/20 0.39
CA7 P43166 2/20 0.39
CA12 O43570 1/20 0.39
CA14 Q9ULX7 1/20 0.39
AAK1 Q2M2I8 1/20 0.39
POLB P06746 1/20 0.39
SLC1A1 P43005 1/20 0.38
LTA4H P09960 1/20 0.38
RAB9A P51151 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23541030 1.00 PPARA (0.46) PPARANPSR1CTSSPPARGKLK7
SCHEMBL23540403 1.00 PPARA (0.46) PPARANPSR1CTSSPPARGKLK7
SCHEMBL29097240 0.87 CA1 (0.42) L3MBTL1CA1CA7CA12SLC1A1
SCHEMBL29097239 0.87 CA1 (0.42) L3MBTL1CA1CA7CA12SLC1A1
SCHEMBL27132003 0.84 SLC1A1 (0.46) PPARAPPARGCA1CA7SLC1A1
SCHEMBL27029002 0.84 SLC1A1 (0.46) PPARAPPARGCA1CA7SLC1A1
SCHEMBL29026408 0.84 SLC1A1 (0.46) PPARAPPARGCA1CA7SLC1A1
SCHEMBL14037310 0.82 AAK1 (0.39) PPARANPSR1SYKL3MBTL1CA1
SCHEMBL23441825 0.81 PPARA (0.51) PPARANPSR1CTSSPPARGKLK7
SCHEMBL7279136 0.78 PPARA (0.53) PPARANPSR1CTSSPPARGKLK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240424111-A1 Degrader Compounds and Uses Thereof CALICO LIFE SCIENCES LLC (US) 2024-12-26 US disclosed
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof ABBVIE INC. 2024-11-21 US disclosed
EP-4077319-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF Calico Life Sciences LLC (US) 2022-10-26 EP disclosed
WO-2021127586-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof PTPN5, PTPN1, PTPN2 PPARA 3458/4885NPSR1 1907/4885CTSS 2265/4885
US-20240424111-A1 Degrader Compounds and Uses Thereof PTPN1, PTPN2, PTPN5 PPARA 2765/4885NPSR1 1360/4885CTSS 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.